The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China, in December
2019. The most striking manifestation of SARS-CoV-2 is atypical pneumonia and respiratory …

Objective: We report the case of a young woman with postinfectious onset of myasthenia
gravis after COVID-19 with mild respiratory symptoms and anosmia/ageusia 1 month before …

Background The COVID-19 pandemic presents two main concerns for patients with
myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and …

The neurotropic potential and the neurological complications of coronavirus disease of 2019
(COVID-19) are still being uncovered. Those documented so far include headaches, acute …

Discussion COVID-19 infection in MG can be challenging for multiple reasons: infections are
known to trigger MG exacerbations/crises, MG patients may be at increased risk of such …

This is a brief report of a patient who has refractory Myasthenia Gravis, on multiple long-term
immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She …

Abstract Introduction Coronavirus disease 2019 (COVID‐19) has rapidly become a global
pandemic, but little is known about its potential impact on patients with myasthenia gravis …

Introduction Since the onset of the novel coronavirus pandemic, several neurological
complications secondary to SARS‐CoV‐2 infection have been reported, affecting central …

Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for
severe COVID-19. We conducted an observational retrospective study with 15 consecutive …

Objective To describe the clinical characteristics and outcomes of coronavirus disease 2019
(COVID-19) among patients with myasthenia gravis (MG) and identify factors associated with …